-
Initial Treatment Options for HER2+ NSCLC Expand with New Zongertinib Approval
On February 26, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) as an initial treatment option for newly diagnosed patients with advanced...
IN THE SPOTLIGHT
-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects...
BRAF class II-III mutations in NSCLC: a single center experience
MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy
MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy
Ahmet Dirican: New Targeted Option for HER2-Mutant NSCLC
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity
Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation
Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation
Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy
Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy